Peritoneal carcinomatosis is metastatic cancer that forms in the membrane inside your abdomen (peritoneum). It happens when cancer from a different part of your body (usually your ovaries or colon) spreads to your peritoneum. There’s no cure, but surgery and a form of chemotherapy called HIPEC help people with this disease live longer.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Peritoneal carcinomatosis is cancer that’s spread to your peritoneum. Your peritoneum is a membrane that lines your abdominal and pelvic cavities. It coats several organs housed inside these cavities. With peritoneal carcinomatosis, cancer that’s started in a different organ travels to this membrane and forms tumors there. It’s different from cancer that starts in your peritoneum (primary peritoneal cancer).
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Any type of cancer can spread to your peritoneum. But the primary (originating) cancers most likely to lead to peritoneal carcinomatosis are:
Cancers that have spread, like peritoneal carcinomatosis, are also called late-stage or metastatic cancers. They’re usually more serious than early-stage cancers. But treatments can help slow disease progression and help you live longer.
Peritoneal carcinomatosis doesn’t usually cause symptoms until it affects a large portion of your peritoneum. At this point, the condition may cause fluid build-up in your abdomen called ascites.
Related symptoms include:
These symptoms are common across lots of conditions. And many of them aren’t as serious as peritoneal carcinomatosis. But only a healthcare provider can rule out cancer in your peritoneum.
Peritoneal carcinomatosis forms when cancer in one part of your body travels to your peritoneum. Usually, the cancer begins in a nearby organ in your abdomen, like your ovaries or colon.
Advertisement
In about 10% of people with peritoneal carcinomatosis, cancer starts in organs outside of the abdominal cavity. When this happens, cancer cells use the bloodstream or lymphatic system to reach your peritoneum.
Tests that diagnose peritoneal carcinomatosis include:
The PCI is one resource your healthcare provider may use during the diagnostic process to plan treatment. Using this index, providers map the location of the tumor in your abdomen and your small intestine. They assign a score based on the tumor’s size.
This information helps your provider know how likely it is that surgery can get rid of the tumor.
The standard treatment for peritoneal carcinomatosis is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). The goal of cytoreductive surgery is to remove all visible tumors in your peritoneum. HIPEC destroys any remaining microscopic cancer cells. This treatment circulates heated chemotherapy drugs throughout your abdominal cavity. The heat and direct application make it stronger than traditional chemotherapy.
People receive cytoreductive surgery and HIPEC in addition to treatments for primary cancer.
If you’re not a candidate for surgery, you may still need palliative care. This treatment can help you manage symptoms better, no matter your cancer stage or prognosis (likely outcome of treatment).
Research shows that CRS and HIPEC are both safe and effective when people are screened carefully to ensure they’re good candidates for treatment. Results are best when surgery happens at a center that delivers this treatment regularly. But as with any surgery, complications can happen. In rare instances, they can be fatal without emergency care. They include:
Your healthcare provider will discuss potential complications with you beforehand. It’s important to understand how the benefits of treatment outweigh the risks.
Advertisement
CRS and HIPEC treatment have improved the prognosis associated with peritoneal carcinomatosis. Although there’s no cure, this treatment can help you live longer.
The five-year survival rate for people who receive CRS that removes all signs of the tumor is 45%. This means that 45% of people who receive CRS successfully are alive five years later. But the five-year survival rate is less than 10% when surgery can’t remove all the cancer. Other factors that play a role in your prognosis include:
Your healthcare provider can explain the factors that impact your likely outcome.
Living with any metastatic cancer (cancer that has spread) — including peritoneal carcinomatosis — is hard. It causes physical symptoms that can make for challenging days ahead. The uncertainty of not knowing how your body will respond to treatment can take an emotional toll, too.
This is why it’s essential to seek every available resource. This may include getting palliative care to help with symptom management. It may include getting counseling to process the complex emotions surrounding your diagnosis. It’s an especially good idea to join a support group that allows you to connect with others also living with metastatic cancer.
Advertisement
Ask your healthcare provider to recommend resources that can make living with peritoneal carcinomatosis more manageable.
You’ll need regular visits with your healthcare provider to check how treatment is working. In the meantime, contact your provider if you’re experiencing new or worsening symptoms. They may recommend additional treatments or changes to your care plan that can help.
Questions to ask include:
A peritoneal carcinomatosis diagnosis once meant that a person had very little time left. But today, treatments are extending the survival timeline of people with this condition. Still, your experience depends on your unique diagnosis. Your healthcare provider can explain whether you’re a candidate for treatments like cytoreductive surgery and HIPEC. They can also connect you with resources to ensure you’re receiving the support you need to help manage this disease.
Advertisement
Last reviewed on 01/16/2025.
Learn more about the Health Library and our editorial process.